J.D., Texas Tech University cum laude
Ph.D., Neurobiology, University of Alicante cum laude
B.Sc., Biology, University of the Balearic Islands
United States Patent and Trademark Office
District of Columbia
American Intellectual Property Law Association
Dr. Canaves is an associate in the Biotechnology/Chemical Group. He prepares and prosecutes U.S. and foreign patent applications, and conducts validity, infringement, and patentability studies. Dr. Canaves has over 20 years of experience in a broad range of scientific fields, including neuroscience, signal transduction, molecular and cellular biology, structural genomics and proteomics, protein biochemistry, multidrug resistance to anticancer agents, and bioinformatics.
His graduate research focused on the characterization and reversal of multidrug resistance to anthracyclines in murine leukemias. While a postdoctoral researcher at the Department of Biology of the University of California San Diego (UCSD), Dr. Canaves was awarded a grant sponsored by the Dystonia Medical Research Foundation. That research entailed the design of peptides capable of inhibiting neurotransmitter release as potential treatments for dystonias and other neuromuscular diseases (U.S. Patent No. 6,169,074). After joining UCSD’s Department of Chemistry and Biochemistry, Dr. Canaves’ research focused on the biochemical, biophysical, and biocomputational characterization of native and mutant forms of the PKA catalytic and regulatory subunits. Prior to joining Sterne Kessler, Dr. Canaves worked for 5 years as a Project Scientist at the Bioinformatics Core of the Joint Center for Structural Genomics, a Protein Structure Initiative pilot center funded by the National Institute of General Medical Sciences.
While in law school, Dr. Canaves served as a fellow at the Texas Tech University Center for Biodefense Law and Public Policy, and as a law clerk at the Texas Tech University Office of Technology Transfer and Intellectual Property. He also participated in clinical programs in alternative dispute resolution and biosafety and biosecurity law.
J.M. Canaves. “Tools for computational protein annotation and function assignment” in In Silico Technology in Drug Target Identification and Validation (Markel, S. and Leon, D.A. Eds.) CRC Press (2006).
J.S. Chappie *, J.M. Canaves*, G.W. Han, C.L. Rife, Q. Xu and R.C. Stevens. "The first structure of an eukaryotic nicotinic acid phosphoribosyltransferase (NAPRTase) reveals structural heterogeneity among type II PRTases”. Structure 13, 1385-1396 (2005). *Equal contributors.
J.M. Canaves, R. Page, I.A. Wilson and R.C. Stevens. "Protein properties that correlate with crystallization success in Thermotoga maritima: Maximum Clustering Strategy for structural genomics". J. Mol. Biol. 344, 977-991 (2004).
J.M. Canaves, D.A. Leon and S.S. Taylor. "Consequences of cAMP-binding site mutations on the structural stability of the Type I regulatory subunit of cAMP-dependent protein kinase". Biochemistry 39, 15022-15031 (2000).
J.M. Canaves and M. Montal. "Assembly of a ternary complex by the predicted minimal coiled-coil forming domains of syntaxin, SNAP-25 and synaptobrevin: a circular dichroism study". J. Biol. Chem. 273, 34214-34221 (1998).
L.M. Gutierrez*, J.M. Canaves*, A.V. Ferrer-Montiel, J.A. Reig, M. Montal and S. Viniegra. "A peptide that mimics the carboxy terminal domain of SNAP-25 blocks Ca2+-dependent exocytosis in chromaffin cells". FEBS Lett.372, 39-43 (1995). *Equal contributors.
J.M. Canaves, J.A. Ferragut and J.M. Gonzalez-Ros. "Verapamil prevents the effects of daunomycin on the thermotropic phase transition of model lipid bilayers". Biochem. J. 279, 413-418 (1991).
Unsolicited e-mails and information sent to Sterne, Kessler, Goldstein & Fox P.L.L.C. will not be considered confidential or privileged, may be disclosed to others, may not receive a response, and do not create an attorney-client relationship with Sterne Kessler. If you are not already a client of Sterne Kessler, do not include any confidential information in this message.